1111 Lincoln Road
Suite 500
Miami Beach, FL 33139
United States
702 514 4174
https://www.pasithea.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 8
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD & Executive Chairman | 250k | S.O. | 1948 |
Dr. Tiago Reis Marques M.D., Ph.D. | CEO & Director | 480k | S.O. | 1977 |
Mr. Daniel H. Schneiderman | Chief Financial Officer | 345,94k | S.O. | 1978 |
Dr. Graeme Currie Ph.D. | Chief Development Officer | 346,62k | S.O. | 1967 |
Dr. Yassine Bendiabdallah Ph.D. | COO & Head of UK Clinics | S.O. | S.O. | 1984 |
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
L’ISS Governance QualityScore de Pasithea Therapeutics Corp. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..